(Multiple Myeloma) FDA Approves Darzalex Faspro (Daratumumab + Hyaluronidase) with Pomalidomide and Dexamethasone
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
- July 9, 2021
- 1 min read
On July 9, 2021, the U.S. Food and Drug Administration (FDA) approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with pomalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor.
This approval is based on the APOLLO trial (NCT03180736), an open-label, active-controlled trial that randomized 304 patients 1:1 to either the pomalidomide/dexamethasone (Pd) group or the Darzalex Faspro group.
Darzalex Faspro dosing regimen:
- Weeks 1–8: Darzalex Faspro (daratumumab 1,800 mg + hyaluronidase 30,000 units) subcutaneously once weekly
- Weeks 9–24: Once every 2 weeks
- Week 25 onwards: Once every 4 weeks until disease progression or unacceptable toxicity
- Pomalidomide: 4 mg orally once daily on Days 1–21 of a 28-day cycle
- Dexamethasone: 40 mg weekly (reduced to 20 mg for patients ≥76 years)
Results:
- Primary endpoint median PFS: Pd group 6.9 months vs. Darzalex Faspro group 12.4 months
- 37% reduction in disease progression or death risk with Darzalex Faspro
Safety:
Most common adverse events (≥20%) in the Darzalex Faspro group: fatigue, pneumonia, upper respiratory tract infection, and diarrhea.
Recommended dose: Darzalex Faspro 1,800 mg/30,000 units (daratumumab 1,800 mg / hyaluronidase 30,000 units), administered subcutaneously over approximately 3–5 minutes in the abdomen.
Multiple Myeloma | Daratumumab | Darzalex Faspro | FDA Approval
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4